Jon Arnason

Beth Israel Deaconess Medical Center — United States

Medicine · Health Sciences

35h-index8.2kcitations243works4.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(81), Lymphoma Diagnosis and Treatment(67), Chronic Lymphocytic Leukemia Research(67), Cutaneous lymphoproliferative disorders research(27), T-cell and Retrovirus Studies(25)

Publications242 total

Long-term survival with lisocabtagene maraleucel in second-line large B-cell lymphoma from TRANSFORM
Blood Advances·2026Open Access
High complete response rates, low dropout rate, and low-grade toxicities in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) receiving GLPG5101, a fresh, early memory-enriched CAR T-cell therapy with a 7-day vein-to-vein time: Results from the ATALANTA-1 DLBCL cohort
Blood·2025
Firicabtagene autoleucel (firi-cel), a CD22-directed CAR T-cell therapy, for patients with relapsed/refractory large B-cell lymphoma: Results from the phase 2 study (FIRCE-1 Trial)
Blood·2025
Axicabtagene ciloleucel versus tisagenlecleucel in relapsed or refractory diffuse large B-cell lymphoma
Blood·2025Open Access
Lisocabtagene maraleucel (liso-cel) versus standard of care (SOC) for second-line relapsed or refractory large B-cell lymphoma (LBCL): First Results from long-term follow-up of TRANSFORM
Blood·2025Open Access
Phased variant circulating tumor DNA (ctDNA) tracking provides limited additional power in predicting progressive disease compared with duplex variant tracking in patients with Relapsed/Refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL) treated with odronextamab
Blood·2025
High complete response rates and minimal residual disease (MRD) negativity, with durable responses, in high-risk mantle cell lymphoma (MCL) with GLPG5101, a fresh, early memory-enriched CAR T-cell therapy with a 7-day vein-to-vein time: Results from the ATALANTA-1 MCL cohort
Blood·2025
Phase I/II study of acalabrutinib, venetoclax, and obinutuzumab in patients with relapsed/refractory and previously untreated Mantle Cell Lymphoma (MAVO)
Blood·2025· 1 citedOpen Access
Early clearance of circulating tumor DNA and association with odronextamab response in relapsed/refractory FL and DLBCL
Blood Advances·2025· 1 citedOpen Access
Association of Cardiovascular Comorbidities on in-Hospital Outcomes of CAR T-Cell Therapy Recipients in the United States
Oncology·2025
Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study
Journal of Clinical Oncology·2025· 14 citedOpen Access
140 | PHASE 2 TRIAL OF LISOCABTAGENE MARALEUCEL (LISO‐CEL) IN COMBINATION WITH ACALABRUTINIB IN RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMAS (LBCL)
Hematological Oncology·2025Open Access
424 | LONGITUDINAL TARGETED ctDNA ANALYSIS TO ASSESS CD20 and BAFF MUTATIONS IN PATIENTS WITH RELAPSED/REFRACTORY FL OR DLBCL PROGRESSING ON ODRONEXTAMAB IN THE ELM‐2 STUDY
Hematological Oncology·2025Open Access
Characteristics and outcomes of patients with double refractory and double exposed chronic lymphocytic leukemia
Blood Advances·2025· 7 citedOpen Access
Erratum: Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease
Journal of Clinical Oncology·2025
Lisocabtagene Maraleucel (liso-cel) in Patients (Pts) with Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL): Results from the Final Analysis of the MCL Cohort of the Open-Label, Phase 1, Seamless Design, Multicenter Transcend NHL 001 (TRANSCEND) Study
Transplantation and Cellular Therapy·2025· 2 cited
Circulating Tumor DNA (ctDNA) As an Early Outcome Predictor in Patients (Pts) with Second-Line (2L) Large B-Cell Lymphoma (LBCL) after Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) Treatment (Tx) from the Phase 3, Randomized Transform Study
Transplantation and Cellular Therapy·2025
Long‐term results of a phase 1/1b study of ibrutinib plus umbralisib for relapsed/refractory chronic lymphocytic leukemia
HemaSphere·2025Open Access
Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study
Blood·2024· 20 citedOpen Access
Early versus late infectious complications following chimeric antigen receptor-modified T-cell therapy
Leukemia & lymphoma/Leukemia and lymphoma·2024· 4 cited
page 1 of 13Next →

Frequent Co-authors

Jeremy S. Abramson(21), Matthew A. Lunning(16), Tanya Siddiqi(15), Leo I. Gordon(12), Jennifer R. Brown(12), Scott R. Solomon(11), Michael Wang(10), David G. Maloney(10), K. OGASAWARA(10), Robin Joyce(10), Matthew S. Davids(9), David C. Fisher(9), Tina Albertson(8), Caron A. Jacobson(8), Philippe Armand(8), David Avigan(8), Charalambos Andreadis(7), Nilanjan Ghosh(7), Jacob Garcia(7), Dina Stroopinsky(7)